Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16698071 | 0.90 | HTR6 (0.40) | HTR6KCNH2 | |
| SCHEMBL16697923 | 0.89 | HTR6 (0.40) | HTR6KCNH2 | |
| SCHEMBL16698232 | 0.88 | KMT2A (0.40) | HTR6KCNH2 | |
| SCHEMBL16698171 | 0.87 | CHRM1 (0.41) | HTR6 | |
| SCHEMBL16697770 | 0.87 | HTR6 (0.40) | HTR6 | |
| SCHEMBL16698273 | 0.86 | HTR6 (0.51) | HTR6 | |
| SCHEMBL16697626 | 0.86 | HTR6 (0.42) | HTR6 | |
| SCHEMBL16698306 | 0.85 | HTR6 (0.42) | HTR6KDM1AKCNH2 | |
| SCHEMBL16698399 | 0.85 | HTR6 (0.46) | HTR6 | |
| SCHEMBL16697743 | 0.84 | HTR6 (0.39) | HTR6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263087-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2016-09-15 | — | — | US | disclosed |
| EP-3066090-A1 | 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | iTeos Therapeutics (BE) | 2016-09-14 | — | — | EP | disclosed |
| US-20150328228-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-11-19 | — | — | US | disclosed |
| US-9126984-B2 | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use | ITEOS THERAPEUTICS SA (BE) | 2015-09-08 | — | — | US | disclosed |
| WO-2015067782-A1 | 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-05-14 | — | — | WO | disclosed |
| US-20150133422-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS SA (BE) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133422-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | HTR6 101/4885NR1H2 2649/4885NR1H3 2576/4885 |
| US-20160263087-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, TPH1 | HTR6 84/4885NR1H2 1187/4885NR1H3 1137/4885 |
| US-20150328228-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | HTR6 144/4885NR1H2 1511/4885NR1H3 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.